Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | u7767aa | OT |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | UNK | Y005351 | OT |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | Y009786 | OT |
no additional AE; HCP called to report a patient received ROTATEQ, VAXELIS and VAXNEUVANCE at 41 days instead of the recommended 42 day vaccination schedule. No side effects or symptoms reported. No Additional AE/ No PQC.; This spontaneous report was received from an other health professional and refers to a 1-month-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 03-Jan-2025, the patient was vaccinated with Pneumococcal 15-valent Conjugate Vaccine Injection (lot #Y005351, expiration date: 08-Jan-2027) 0.5 mL, Rotavirus Vaccine, Live, Oral, Pentavalent (Rotateq), (lot #Y009786, expiration date: 20-Nov-2025) 2 mL, administered by Oral route and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine (VAXELIS), Injection (lot #u7767aa was an invalid lot#, expiration date was reported as 26-May-2026) 0.5 mL at 41 days instead of the recommended 42 day vaccination schedule (Product administered to patient of inappropriate age). No side effects or symptoms reported. No Additional AE (no adverse event).